Johnson & Johnson claim to have up to 800 million vaccines for the coronavirus available by early 2021.
As previously reported, Johnson & Johnson human vaccine trials will commence in September this year.
Joseph Wolk, Executive Vice President and Chief Financial Officer for Johnson & Johnson said:
“The timeline still is pretty certain.”
“We’re manufacturing at risk to ensure that should the clinical development and the trials be successful; we are in a position to kind of flip the switch and ready to go to create great access across the globe.”
Johnson & Johnson aims to be producing up to 1 billion vaccine doses by the end of 2021.
In order to achieve this goal, a $1 billion investment was announced by Johnson & Johnson and the Federal Biomedical Advanced Research and Development Authority last month.
A new manufacturing facility has been planned in the US supplementary to the company’s plant in the Netherlands.
The plant in the Netherlands can produce up to 300 million doses.
The factory in the US will be ready late 2020 to early 2021 according to Wolk.